Oppenheimer Asset Management Inc. Grows Position in Silk Road Medical, Inc (NASDAQ:SILK)

Oppenheimer Asset Management Inc. increased its position in shares of Silk Road Medical, Inc (NASDAQ:SILKFree Report) by 44.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,354 shares of the company’s stock after acquiring an additional 7,781 shares during the quarter. Oppenheimer Asset Management Inc. owned about 0.07% of Silk Road Medical worth $380,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Wasatch Advisors LP raised its stake in shares of Silk Road Medical by 61.7% during the 2nd quarter. Wasatch Advisors LP now owns 5,246,961 shares of the company’s stock worth $170,474,000 after acquiring an additional 2,002,423 shares in the last quarter. Wasatch Advisors Inc. raised its stake in shares of Silk Road Medical by 8.1% during the 1st quarter. Wasatch Advisors Inc. now owns 4,087,829 shares of the company’s stock worth $168,786,000 after acquiring an additional 306,577 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Silk Road Medical by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 3,195,288 shares of the company’s stock worth $143,788,000 after acquiring an additional 38,613 shares in the last quarter. BlackRock Inc. raised its stake in shares of Silk Road Medical by 10.6% during the 2nd quarter. BlackRock Inc. now owns 2,965,739 shares of the company’s stock worth $96,357,000 after acquiring an additional 283,580 shares in the last quarter. Finally, Alliancebernstein L.P. raised its stake in shares of Silk Road Medical by 1.3% during the 2nd quarter. Alliancebernstein L.P. now owns 2,493,003 shares of the company’s stock worth $80,998,000 after acquiring an additional 31,132 shares in the last quarter.

Analyst Ratings Changes

SILK has been the subject of several recent analyst reports. Stifel Nicolaus upgraded shares of Silk Road Medical from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $9.00 to $20.00 in a research note on Friday, January 19th. Wolfe Research upgraded shares of Silk Road Medical from an “underperform” rating to a “peer perform” rating in a research note on Tuesday, October 24th. Finally, Lake Street Capital started coverage on shares of Silk Road Medical in a research note on Wednesday, January 3rd. They set a “buy” rating and a $20.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $24.91.

Read Our Latest Research Report on SILK

Silk Road Medical Stock Performance

NASDAQ:SILK opened at $16.73 on Friday. Silk Road Medical, Inc has a 1-year low of $6.08 and a 1-year high of $54.69. The company’s fifty day moving average price is $12.76 and its 200-day moving average price is $13.78. The company has a current ratio of 10.03, a quick ratio of 9.11 and a debt-to-equity ratio of 0.49.

Silk Road Medical (NASDAQ:SILKGet Free Report) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.03. The firm had revenue of $44.44 million for the quarter, compared to analyst estimates of $44.40 million. Silk Road Medical had a negative net margin of 32.81% and a negative return on equity of 35.40%. As a group, analysts anticipate that Silk Road Medical, Inc will post -1.51 EPS for the current year.

About Silk Road Medical

(Free Report)

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a specialty balloon for the TCAR procedure.

Featured Stories

Want to see what other hedge funds are holding SILK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Silk Road Medical, Inc (NASDAQ:SILKFree Report).

Institutional Ownership by Quarter for Silk Road Medical (NASDAQ:SILK)

Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.